Development of analysis methods for clinical research of NDB data

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K12119
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 62010:Life, health and medical informatics-related
• Research Institution: Chiba University
• Principal Investigator: Suzuki Takahiro 千葉大学, 医学部附属病院, 准教授 (40323422)
• Co-Investigator(Kenkyū-buntansha): 花岡 英紀 千葉大学, 医学部附属病院, 教授 (80361426)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: ビックデータ / real world data

Outline of Final Research Achievements

We published several articles on the efficacy and safety of anti-rheumatic drugs (biologics) among drugs and presided at two symposia on clinical research applications of NDB data at the Society for Medical Informatics. As for receipt analysis of immune checkpoint inhibitors for lung cancer, we demonstrated that 3.76% of lung cancer patients were using immune checkpoint inhibitors. In non-small cell carcinoma, 4,447 patients received pembrolizumab and 677 patients received nivolumab, comparing one year and three years from start, 17% of 1326 patients received nivolumab at one year and 6% at three years.

Free Research Field

医療情報

Academic Significance and Societal Importance of the Research Achievements

NDBを用いて関節リウマチの生物学的製剤と肺がんの免疫チェックポイント阻害薬を対象とした一般の臨床研究に伍する研究ができることを示した。NDB研究はNDBが世界において稀有な巨大かつ悉皆性をもったレセプトデータベースであり、他国ではこれと同等の研究はできないことから、ビッグデータ解析でわが国の独壇場になる可能性がある。この2分野の領域を超えて他分野の多くの医学研究者に知っていただくことの意義は大きい。